Journée mondiale du paludisme 2015 : les Etats-Unis prônent une lutte collective

Le programme de lutte contre le paludisme des États Unis d’Amérique à travers l’Initiative du Président contre le Paludisme (PMI) continue d’être leader dans la lutte mondiale contre le paludisme. En neuf ans, cette initiative de par ses contributions financières et techniques a été un catalyseur majeur dans les progrès remarquables réalisés dans plusieurs pays dans la réduction de la charge dévastatrice du paludisme sur la mortalité des enfants…

Malaria vaccine offers partial protection: final results

The world's most advanced malaria candidate vaccine offers young children partial protection that wanes with time, but could shield millions against the deadly parasite, its developers said Friday.
Researchers published the final results of a years-long trial with the drug RTS,S in The Lancet medical journal.
"We finally have in our sights a candidate vaccine that could have a real impact on this terrible disease that affects many children during their first years of life," principal investigator Kwaku Asante said in a statement. 

New genetic mutation could signal start of malaria drug resistance in Africa

Early indicators of the malaria parasite in Africa developing resistance to the most effective drug available have been confirmed, according to new research published in Antimicrobial Agents and Chemotherapy.
Researchers at the London School of Hygiene & Tropical Medicine found Plasmodium falciparum malaria parasites with a mutation to the gene Ap2mu were less sensitive to the antimalarial drug artemisinin.

Public-private partnerships 'vital' in fight against malaria

The Ebola virus death toll in west Africa is a reminder that tropical and neglected diseases such as malaria, Aids, tuberculosis and dengue remain a prominent global health challenge. The world health organization (WHO) estimates that over one billion people suffer from one or more neglected diseases. April is dedicated to health issues as part of the European year for development and world malaria day is on 25 April. In this context, I believe the EU should strengthen its leadership on global health and development policy, starting with the fight against malaria.

Surveillance identifies gaps in malaria control efforts

Although malaria burden is gradually falling globally, it remains high and continues to rise in high-transmission areas, especially in rural Africa, a two-year surveillance in Uganda has shown.
According to the researchers who undertook the study, successes recorded for malaria control in Sub-Saharan Africa are mostly limited to low-transmission areas, noting that research in high-transmission regions are needed.

Study of African Birds Reveals Hotbed of Malaria Parasite Diversity

When you think of tropical biodiversity, you may picture flocks of colorful birds flitting through lush foliage—but what you are less likely to imagine is the plethora of parasites and pathogens pulsing through the bloodstreams of those birds. Among these microscopic organisms are Plasmodium parasites, best known for causing malaria in humans, birds and many other vertebrates.

Cancer drugs may treat malaria parasites

Researchers recently published the details of a study that suggests cancer drugs may successfully treat the parasites that cause malaria.
“With the use of cancer drugs, which target the infected liver cell instead of the parasite directly, we minimize the risk of promoting drug resistance,” Seattle BioMed’s Alexis Kaushansky said.
This new discovery is good news for regions affected by malaria as well as regions affected by drug-resistant illnesses.

New vaccine fights placental malaria

The University of Copenhagen, Biotech Company and ExpreS2ion Biotechnologies recently announced the creation of a vaccine candidate to fight against placental malaria, a strain of the disease that only affects pregnant women.
The vaccine uses ExpreS2ion’s proprietary protein expression technology called ExpreS3 to carry the malaria antigen into the body. It has taken many years of research to reach this point, and the new vaccine will soon be ready for testing in humans.

Malaria vaccine trial conducted in Equatorial Guinea

The first clinical trial of PfSPZ, a novel malaria vaccine developed by a U.S. biotechnology company called Sanaria, was hosted in Equatorial Guinea.
There were a total of three volunteers in the trial, which occurred in the La Paz Medical Center in Sipopo.
The vaccine provokes a strong immune response that is intended to fight against the parasite responsible for malaria.
Early tests suggest that the new drug may be the safest and most efficient malaria vaccine on the market.

Protection Without a Vaccine

Last month, a team of scientists announced what could prove to be an enormous step forward in the fight against H.I.V.
Scientists at Scripps Research Institute said they had developed an artificial antibody that, once in the blood, grabbed hold of the virus and inactivated it. The molecule can eliminate H.I.V. from infected monkeys and protect them from future infections.